NCT04122235

Brief Summary

This study compares traditional follow-up of gynaecological cancer patients to an alternative follow-up model. In the alternative follow-up model the patients will meet a nurse at every second consultation. The nurse will focus on psychosocial health and educate the patients in the use of a study specific smartphone-application.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
755

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

12 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 2, 2019

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 10, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

November 18, 2019

Completed
6.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 27, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 27, 2026

Completed
Last Updated

March 30, 2026

Status Verified

March 1, 2026

Enrollment Period

6.4 years

First QC Date

September 2, 2019

Last Update Submit

March 27, 2026

Conditions

Keywords

follow-upapplifestyleempowermentnurse-led

Outcome Measures

Primary Outcomes (1)

  • Patients' score on the Health Education Impact Questionnaire (HEI-Q)

    Evaluating the immediate effects of self-management interventions in cancer follow-up. It contains the following domains: Health-directed activities, Positive and active engagement in life, Emotional distress, Constructive attitudes and approaches, Self-monitoring and insight, Skill and technique acquisition, Social integration and support, Health service navigation. Individuals are asked to indicate their level of agreement with 42 statements across the eight domains on four-point Likert scales (1 "strongly disagree" to 4 "Strongly agree"). Higher scores indicate greater performance of specific self-management behaviors. Higher scores on the emotional well-being domain denote higher levels of negative affect. Data from each domain will be used individually and the results reported as mean domain score. The primary outcome is the change of the insight subscale scores of the HEI-Q from right after treatment (baseline) to 12 months after treatment.

    Assessed right after initial treatment, and 3, 6, 12, 24 and 36 months after treatment

Secondary Outcomes (19)

  • Patients' score on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), measuring ´Health related quality of life (HRQL)

    Questionnaires are administered at end of treatment, 3, 6, 12, 24 and 36 months after treatment, respectively

  • Change adherence to physical activity recommendations

    Change from baseline to 12, 24 and 36 months after completion of primary treatment

  • Physical activity goals

    Change from baseline to 12, 24 and 36 months after completion of primary treatment

  • Changes in physical activity level based on International Physical Activity Questionnaire - Short Form (IPAQ)

    Change from baseline to 12, 24 and 36 months after completion of primary treatment

  • Patients' score on the Health Education Impact Questionnaire (HEI-Q)

    Questionnaires are administered at end of treatment, 3, 6, 12, 24 and 36 months after treatment, respectively

  • +14 more secondary outcomes

Study Arms (2)

Intervention arm

EXPERIMENTAL

New follow-up model

Other: LETSGO follow-up

Control arm

NO INTERVENTION

Usual care

Interventions

Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app

Intervention arm

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsGynecological cancer
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Histologically verified gynaecological cancer
  • Cervical cancer restricted to squameous cell carcinoma, adeno carcinoma and adeno-squameous carcinoma) or
  • Endometrial cancer or
  • Ovarian cancer (restricted to epithelial type) or
  • Vulvar cancer
  • Must have completed primary treatment and scheduled to follow-up

You may not qualify if:

  • Participating in other cancer treatment trial or follow-up trial
  • Cervical cancer patients treated with trachelectomy
  • On maintenance therapy
  • Dementia or other mental/cognitive impairment
  • Illiterate in Norwegian

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Innlandet Hospital Gjøvik

Gjøvik, Oppland, 2819, Norway

Location

Sorlandet Hospital

Kristiansand, Vest Agder, 4604, Norway

Location

Sørlandet hospital Arendal

Arendal, Norway

Location

Nordland Hospital

Bodø, Norway

Location

Innlandet Hospital Lillehammer

Lillehammer, 2609, Norway

Location

Akershus University Hospital

Lørenskog, Norway

Location

Oslo University Hospital

Oslo, Norway

Location

Østfold Hospital Trust

Sarpsborg, Norway

Location

Stavanger University Hospital

Stavanger, Norway

Location

University Hospital of North Norway

Tromsø, Norway

Location

St.Olavs Hospital

Trondheim, Norway

Location

Vestfold Hospital Trust

Tønsberg, Norway

Location

Related Publications (1)

  • Vistad I, Skorstad M, Demmelmaier I, Smastuen MC, Lindemann K, Wisloff T, van de Poll-Franse LV, Berntsen S. Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking. BMJ Open. 2021 Jul 12;11(7):e050930. doi: 10.1136/bmjopen-2021-050930.

MeSH Terms

Conditions

Genital Neoplasms, FemaleOvarian NeoplasmsEndometrial NeoplasmsUterine Cervical NeoplasmsVulvar NeoplasmsAlzheimer DiseaseEmpowerment

Condition Hierarchy (Ancestors)

Urogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesEndocrine Gland NeoplasmsOvarian DiseasesAdnexal DiseasesEndocrine System DiseasesGonadal DisordersUterine NeoplasmsUterine DiseasesUterine Cervical DiseasesVulvar DiseasesDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersSocial BehaviorBehavior

Study Officials

  • Ingvild Vistad, MD, PhD

    Sorlandet Hospital HF

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: A multicenter controlled clinical trial of individualized nurse/physician-led follow-up (treatment group) versus standard care (control group) in approximately 754 women treated for gynecological cancer
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 2, 2019

First Posted

October 10, 2019

Study Start

November 18, 2019

Primary Completion

March 27, 2026

Study Completion

March 27, 2026

Last Updated

March 30, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

At the end of the study, data will be made available (after anonymisation) upon request to the corresponding author. The data collected will be stored for up to 15 years after the end of study. This timeperiod will take into account possible national and international legal restrictions (ie, Norwegian and EU regulations).

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data will be available within one year after end of study (i.e.March 2026), and the data will be made accessible for up to 5 years. Extensions will be considered on a case-by-case basis.
Access Criteria
Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).

Locations